OPKO Health (NASDAQ:OPK) Stock Rating Upgraded by LADENBURG THALM/SH SH

LADENBURG THALM/SH SH upgraded shares of OPKO Health (NASDAQ:OPK - Free Report) to a strong-buy rating in a research report report published on Tuesday morning,Zacks.com reports.

Other equities research analysts have also recently issued reports about the company. Wall Street Zen cut OPKO Health from a "hold" rating to a "sell" rating in a research report on Monday, May 5th. HC Wainwright reissued a "buy" rating and issued a $3.00 price target on shares of OPKO Health in a report on Monday, April 7th. JPMorgan Chase & Co. started coverage on shares of OPKO Health in a report on Friday, April 25th. They set a "neutral" rating on the stock. Finally, Barrington Research reaffirmed an "outperform" rating and set a $2.25 price objective on shares of OPKO Health in a research report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $2.75.

OPKO Health Stock Performance

OPK stock traded down $0.01 during mid-day trading on Tuesday, reaching $1.35. 1,758,039 shares of the stock traded hands, compared to its average volume of 3,877,104. The firm has a market capitalization of $1.07 billion, a PE ratio of -19.28 and a beta of 1.34. The business has a 50-day moving average of $1.32 and a two-hundred day moving average of $1.49. OPKO Health has a 52 week low of $1.21 and a 52 week high of $2.04. The company has a quick ratio of 2.28, a current ratio of 2.49 and a debt-to-equity ratio of 0.25.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The business had revenue of $149.90 million for the quarter, compared to analyst estimates of $163.13 million. OPKO Health had a negative return on equity of 2.85% and a negative net margin of 5.66%. OPKO Health's revenue for the quarter was down 13.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.12) EPS. As a group, equities analysts predict that OPKO Health will post -0.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of OPK. Oak Thistle LLC bought a new stake in shares of OPKO Health in the 1st quarter valued at approximately $26,000. GM Advisory Group LLC acquired a new stake in OPKO Health in the 1st quarter valued at $33,000. Cerity Partners LLC bought a new stake in OPKO Health in the first quarter valued at $36,000. Pallas Capital Advisors LLC acquired a new position in OPKO Health during the first quarter worth $43,000. Finally, Voleon Capital Management LP bought a new position in shares of OPKO Health during the first quarter valued at $45,000. 64.63% of the stock is owned by institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.